Cargando…

Significance of S-phase fraction and hormone receptor content in the management of young breast cancer patients.

Tumours from 336 breast cancer patients under the age of 50 were analysed for hormone receptor content and by DNA flow cytometry. Sixty-six percent of the tumours were positive for estrogen receptors (ER), 60% were progesterone receptor (PR) positive and 42% showed DNA diploid profiles. DNA hypodipl...

Descripción completa

Detalles Bibliográficos
Autores principales:	Stål, O., Carstensen, J., Hatschek, T., Nordenskjöld, B.
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 1992
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1977426/ https://www.ncbi.nlm.nih.gov/pubmed/1419611

Ejemplares similares

S-phase fraction and survival benefit from adjuvant chemotherapy or radiotherapy of breast cancer.
por: Stål, O., et al.
Publicado: (1994)

Flow cytometric analysis of S-phase fraction in breast carcinomas using gating on cells containing cytokeratin. South East Sweden Breast Cancer Group.
por: Wingren, S., et al.
Publicado: (1994)

Time dependent effects of adjuvant tamoxifen therapy on cerebrovascular disease: results from a randomised trial
por: Rosell, J, et al.
Publicado: (2011)

RAB6C is an independent prognostic factor of estrogen receptor-positive/progesterone receptor-negative breast cancer
por: Fohlin, Helena, et al.
Publicado: (2020)

Low RAB6C expression is a predictor of tamoxifen benefit in estrogen receptor-positive/progesterone receptor-negative breast cancer
por: Fohlin, Helena, et al.
Publicado: (2020)

Genetic variants of CYP3A5, CYP2D6, SULT1A1, UGT2B15 and tamoxifen response in postmenopausal patients with breast cancer
por: Wegman, Pia, et al.
Publicado: (2007)

Breast cancer survival and incidence of second primary cancers after 30 years in a randomized study of two versus five years of adjuvant tamoxifen therapy
por: Nordenskjöld, Anna, et al.
Publicado: (2023)

Oestrogen receptor co-activator AIB1 is a marker of tamoxifen benefit in postmenopausal breast cancer
por: Weiner, M., et al.
Publicado: (2013)

p53 as a prognostic factor in stage I breast cancer. South-East Sweden Breast Cancer Group.
por: Stenmark-Askmalm, M., et al.
Publicado: (1995)

Androgen receptor expression predicts beneficial tamoxifen response in oestrogen receptor-α-negative breast cancer
por: Hilborn, Erik, et al.
Publicado: (2016)

Progesterone receptor positivity is a predictor of long-term benefit from adjuvant tamoxifen treatment of estrogen receptor positive breast cancer
por: Nordenskjöld, Anna, et al.
Publicado: (2016)

Expression of Akt kinases related to ErbB2 and results of adjuvant therapy of breast cancer
por: Stal, O, et al.
Publicado: (2000)

C–X–C ligand 10 and C–X–C receptor 3 status can predict tamoxifen treatment response in breast cancer patients
por: Hilborn, Erik, et al.
Publicado: (2014)

Raptor localization predicts prognosis and tamoxifen response in estrogen receptor-positive breast cancer
por: Bostner, Josefine, et al.
Publicado: (2017)

17β-Hydroxysteroid Dehydrogenase Type 14 Is a Predictive Marker for Tamoxifen Response in Oestrogen Receptor Positive Breast Cancer
por: Sivik, Tove, et al.
Publicado: (2012)

Lack of prognostic significance of DNA ploidy and S phase fraction in breast cancer.
por: Stanton, P. D., et al.
Publicado: (1992)

DNA ploidy and S-phase fraction as prognostic factors in patients with uveal melanomas.
por: Karlsson, M., et al.
Publicado: (1995)

Hormonal content and potency of oral contraceptives and breast cancer risk among young women
por: Althuis, M D, et al.
Publicado: (2003)

PTPN2 deficiency along with activation of nuclear Akt predict endocrine resistance in breast cancer
por: Karlsson, Elin, et al.
Publicado: (2018)

Predictive relevance of HOXB13 protein expression for tamoxifen benefit in breast cancer
por: Jerevall, Piiha-Lotta, et al.
Publicado: (2010)

Paclitaxel, Epirubicin and Capecitabine (TEX) as First-Line Treatment for Metastatic Breast Cancer: a Pilot Phase I/II Feasibility Study
por: Einbeigi, Z., et al.
Publicado: (2008)

17β-Hydroxysteroid dehydrogenases involved in local oestrogen synthesis have prognostic significance in breast cancer
por: Gunnarsson, C, et al.
Publicado: (2005)

The Effect of Young Age in Hormone Receptor Positive Breast Cancer
por: Lee, Minna K., et al.
Publicado: (2015)

Assessment of 25-Year Survival of Women With Estrogen Receptor–Positive/ERBB2-Negative Breast Cancer Treated With and Without Tamoxifen Therapy: A Secondary Analysis of Data From the Stockholm Tamoxifen Randomized Clinical Trial
por: Dar, Huma, et al.
Publicado: (2021)

Genotype of metabolic enzymes and the benefit of tamoxifen in postmenopausal breast cancer patients
por: Wegman, Pia, et al.
Publicado: (2005)

Akt kinases in breast cancer and the results of adjuvant therapy
por: Stål, Olle, et al.
Publicado: (2003)

Dynamic evaluation of the immune infiltrate and immune function genes as predictive markers for neoadjuvant chemotherapy in hormone receptor positive, HER2 negative breast cancer
por: Matikas, Alexios, et al.
Publicado: (2018)

The effects of PTPN2 loss on cell signalling and clinical outcome in relation to breast cancer subtype
por: Veenstra, Cynthia, et al.
Publicado: (2019)

Prognostic Significance of Substance P/Neurokinin 1 Receptor and Its Association with Hormonal Receptors in Breast Carcinoma
por: Mehboob, Riffat, et al.
Publicado: (2021)

IP6K2 predicts favorable clinical outcome of primary breast cancer
por: Sandström, Josefine, et al.
Publicado: (2021)

Hormonal Receptor Status Determines Prognostic Significance of FGFR2 in Invasive Breast Carcinoma
por: Braun, Marcin, et al.
Publicado: (2020)

Determination and clinical significance of bone pseudoprogression in hormone receptor-positive metastatic breast cancer
por: Lin, Mingxi, et al.
Publicado: (2021)

Prognostic significance of p53 overexpression in primary breast cancer; a novel luminometric immunoassay applicable on steroid receptor cytosols.
por: Borg, A., et al.
Publicado: (1995)

Activation of Akt, mTOR, and the estrogen receptor as a signature to predict tamoxifen treatment benefit
por: Bostner, Josefine, et al.
Publicado: (2012)

Prognostic significance of terminal transferase activity and glucocorticoid receptor levels in acute myeloid leukemia.
por: Skoog, L., et al.
Publicado: (1984)

Clinical significance and prognostic value of receptor conversion in hormone receptor positive breast cancers after neoadjuvant chemotherapy
por: Yang, Libo, et al.
Publicado: (2018)

Muscle Androgen Receptor Content but Not Systemic Hormones Is Associated With Resistance Training-Induced Skeletal Muscle Hypertrophy in Healthy, Young Men
por: Morton, Robert W., et al.
Publicado: (2018)

Objective measurement and clinical significance of IDO1 protein in hormone receptor-positive breast cancer
por: Carvajal-Hausdorf, Daniel E., et al.
Publicado: (2017)

Prognostic value of the S-phase fraction of breast cancer.
por: Remvikos, Y.
Publicado: (1993)

Hormones, Receptors and Breast Cancer
por: Barnes, D. M.
Publicado: (1979)

Cannot write session to /tmp/vufind_sessions/sess_a90oqpgg3de4jgi4c6pq68fief